Asian Tech Press (Jan 25) -- Pfizer and BioNTech have reportedly launched clinical trials on a Covid-19 vaccine targeting the Omnicron strain. The two pharmaceutical companies said they began enrolling adults aged 18 to 55 in the United States and South Africa to examine the vaccine's safety, tolerability, and the immune response it produces.

Pfizer said preliminary study results are expected to be published in the first half of this year. If the vaccine against the Omicron strain proves safe and effective, the company may ask U.S. regulators to authorize it and begin selling it in March, Pfizer CEO said.